Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach

Table 5 Differences in adverse events between chemoradiation therapy, chemotherapy and chemotherapy plus chemoradiation therapy groups, n (%)

Complications	Group A, n = 65			Group B, n = 62			Group C, n = 208			P value
	Grade 2	Grade 3	Grade 4	Grade 2	Grade 3	Grade 4	Grade 2	Grade 3	Grade 4
Febrile neutropenia	-	-	-	-	-	-	-	1 (0.5)	-	0.736
Neutropenia	15 (23.1)	3 (4.6)	5 (7.7)	15 (24.2)	15 (24.2)	6 (9.7)	63 (30.3)	68 (32.7)	21 (10.1)	< 0.001
Anemia	14 (21.5)	1 (1.5)	1 (1.5)	19 (30.6)	2 (3.2)	1 (1.6)	84 (40.4)	17 (8.2)	1 (0.5)	0.001
Thrombocytopenia	-	1 (1.5)	-	5 (8.1)	2 (3.2)	1 (1.6)	16 (7.7)	7 (3.4)	2 (1.0)	0.037
Hypertransaminasemia	3 (4.6)	1 (1.5)	-	3 (4.8)	1 (1.6)	-	24 (11.5)	12 (5.8)	3 (1.4)	0.006
N/V	4 (6.2)	-	-	5 (8.1)	2 (3.2)	-	10 (4.8)	4 (1.9)	-	0.441
Diarrhea	4 (6.2)	-	-	3 (4.8)	1 (1.6)	-	16 (7.7)	2 (1.0)	-	0.735
Anorexia	5 (7.7)	1 (1.5)	-	4 (6.5)	-	-	14 (6.7)	-	-	0.770
Abdominal pain	3 (4.6)	-	-	3 (4.8)	-	-	10 (4.8)	1 (0.5)	-	0.973
GERD	4 (6.2)	-	-	1 (1.6)	-	-	7 (3.4)	-	-	0.374
Fatigue	5 (7.7)	2 (3.1)	-	2 (3.2)	1 (1.6)	-	19 (9.1)	2 (1.0)	-	0.408
Mucositis	1 (1.5)	-	-	2 (3.2)	1 (1.6)	-	5 (2.4)	1 (0.5)	-	0.545
Peripheral neuropathy	-	-	-	-	1 (1.6)	-	-	3 (1.4)	-	0.611

Group A: Chemoradiation therapy; Group B: Chemotherapy, Group C: Chemotherapy plus chemoradiation therapy. GERD: Gastroesophageal reflux disease; N/V: Nausea and vomiting.